Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma.
Huen A, Haverkos BM, Zain J, Radhakrishnan R, Lechowicz MJ, Devata S, Korman NJ, Pinter-Brown L, Oki Y, Barde PJ, Nair A, Routhu KV, Viswanadha S, Vakkalanka S, Iyer SP.
Huen A, et al.
Cancers (Basel). 2020 Aug 15;12(8):2293. doi: 10.3390/cancers12082293.
Cancers (Basel). 2020.
PMID: 32824175
Free PMC article.